Can you take Bleo 15k with Omacetaxine?

Omacetaxine has a moderate potential interaction with Bleeding Disorder.

Omacetaxine can cause severe thrombocytopenia. Bleeding events, including fatalities from cerebral hemorrhage, and severe, non-fatal, gastrointestinal hemorrhages have been reported in clinical trials. Perform complete blood counts, including platelet counts weekly during induction and initial maintenance cycles. It is recommended to avoid anticoagulants, aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs) when the platelet count is less than 50,000/µL as they may increase the risk of bleeding. Caution is recommended when using this agent in patients at risk of bleeding episodes.

Omacetaxine has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

The use of omacetaxine might cause hematological toxicities. Patients with neutropenia are at increased risk for infections, and should be monitored frequently and advised to contact a physician if they have symptoms of infection or fever. It is recommended to monitor complete blood counts (CBCs) weekly during induction and initial maintenance cycles and every two weeks during later maintenance cycles, as clinically indicated. After initial maintenance cycles, monitor CBCs every two weeks or as clinically indicated. Care should be exercised when using omacetaxine in patients with hematological disorders.

Omacetaxine has a moderate potential interaction with Diabetes Mellitus.

The use of omacetaxine can induce glucose intolerance. Hyperglycemia has been reported in patients using omacetaxine. It is recommended to monitor blood glucose levels frequently, especially in patients with a history of diabetes or in those with risk factors for diabetes. Avoid the use of omacetaxine in patients with poorly controlled diabetes.

The bleomycin in Bleo 15k has a moderate potential interaction with Liver Disease.

The effect of hepatic insufficiency on the pharmacokinetics of bleomycin has not been evaluated. However, hepatic toxicity, beginning as a deterioration in liver function tests, has been reported. These toxicities may occur at any time after initiation of therapy. Caution and monitoring is advised if bleomycin is used in patients with liver impairment.

The bleomycin in Bleo 15k has a major potential interaction with Pulmonary Impairment.

Pulmonary pneumonitis occurs in 10% of patients during bleomycin therapy and 1% progress to pulmonary fibrosis and death. Although pulmonary toxicity is age and dose related, occurring primarily in patients over 70 years of age and in those receiving a total dose > 400 units, it has occurred in younger patients at a lower dose. Extreme caution should be exercised when administering bleomycin in patients with compromised pulmonary function. Patients should be instructed to immediately report symptoms of dyspnea, cough, or congestion. Close clinical monitoring of pulmonary function is recommended.

The bleomycin in Bleo 15k has a major potential interaction with Renal Dysfunction.

Bleomycin is primarily eliminated by the kidney. Approximately 60% to 70% of bleomycin is excreted in the urine as active drug. Moderate renal failure reduces elimination to < 20% of the drug. Extreme caution should be exercised when administering bleomycin in patients with existing or predisposition to significantly compromised renal function. Close clinical monitoring of renal function is recommended.

Omacetaxine has a moderate potential interaction with Thrombocytopenia.

Omacetaxine can cause severe thrombocytopenia. Bleeding events, including fatalities from cerebral hemorrhage, and severe, non-fatal, gastrointestinal hemorrhages have been reported in clinical trials. Perform complete blood counts, including platelet counts weekly during induction and initial maintenance cycles. It is recommended to avoid anticoagulants, aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs) when the platelet count is less than 50,000/µL as they may increase the risk of bleeding. Caution is recommended when using this agent in patients at risk of bleeding episodes.